Use of butyric acid for the preparation of a medicament for the treatment of anemia induced by inflammatory bowel disease

By using butyrate to inhibit the binding of Sp1 and HDAC1 and promote FPN expression, the problem of inflammatory anemia caused by iron ion imbalance in existing technologies was solved, achieving effective regulation of iron metabolism and relief of anemia.

CN116059193BActive Publication Date: 2026-06-12ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
ZHEJIANG UNIV
Filing Date
2023-03-14
Publication Date
2026-06-12

Smart Images

  • Figure CN116059193B_ABST
    Figure CN116059193B_ABST
Patent Text Reader

Abstract

This application discloses the application of butyric acid in the preparation of drugs for treating anemia caused by inflammatory bowel disease (IBD), relating to the field of biotechnology. The butyric acid in this application can inhibit the binding of Sp1 and HDAC1, promoting the formation of open chromatin conformations in the FPN promoter region to maintain FPN expression, thereby reversing anemia symptoms caused by enteritis. This application is the first to discover the regulation of macrophage iron metabolism by short-chain fatty acids, alleviating the effects of inflammatory anemia by promoting macrophage iron ion export. This application proposes a new model for the regulation of immune cell function by gut microbiota metabolites, potentially providing a new strategy for the clinical treatment of anemia in IBD patients.
Need to check novelty before this filing date? Find Prior Art